Protagonist Therapeutics, Inc Revenue
Protagonist Therapeutics, Inc (PTGX) reported Revenue of $213.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-05
- Protagonist Therapeutics, Inc revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $213.47M, a 3749.17% increase year-over-year.
- Protagonist Therapeutics, Inc revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $5.55M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month |
|---|---|---|
| 2026-06-30 | $213.47M 10-Q · filed 2026-08-05 | $269.84M 10-Q · filed 2026-08-05 |
| 2025-06-30 | $5.55M 10-Q · filed 2026-08-05 | $33.87M 10-Q · filed 2026-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |